Ubicom Holdings. Inc. · TSE:3937
Ubicom — Q3 2022 Earnings Presentation
30 slides from Ubicom's earnings presentation, Feb 9, 2023
Slide 1: Presentation Materials for FY2022 Q3
FY2022 Q3 Consolidated Business Results Presentation Materials for FY2022 Q3 Ubicom Holdings, Inc. TSE Prime: 3937 February 9, 2023 Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the
Slide 2: FY2022 Q3 Highlights
FY2022 Q3 Highlights While we continue to invest for the second growth phase, operating and ordinary incomes reached record highs for the third quarter. Whereas net income decreased, as among the investment securities held by the company, the valuation loss of investment securities whose market valu
Slide 3: FY2022 Q3 (P/L)
FY2022 Q3 (P/L) Secured increases in net sales, operating income and ordinary income in the cumulative third quarter as the company continued to make investments for the second growth phase and implemented policies to adapt to the external environment in terms of pricing and exchange rates, while de
Slide 4: FY2022 Cumulative Q3 Investment Status
FY2022 Cumulative Q3 Investment Status Against the backdrop of the Economic Security Promotion Bill, greater efforts are made for global supply chain risks and security and intellectual property in the IT industry. In these circumstances, in response to the steepest increase of business inquiries si
Slide 5: FY2022 Q3 Purpose in Increasing Personnel Investment
FY2022 Q3 Purpose in Increasing Personnel Investment Target Market Size (Our calculations) 20 billion yen 50 billion yen 20 billion yen 10 billion yen or more Collaboration with Partnerships with European and Medical Business Pillar Customers U.S. Markets M&A To promote Deepening business To nego
Slide 6: FY2022 Q3 Segment Overview: Global Business
FY2022 Q3 Segment Overview : Global Business Achieved a significant increase in sales on the back of strong demand. After taking into account investments for the second growth phase, the company secured an over-20% increase in profit from the previous year. FY2021 FY2022 Global Business Year-on- Q3
Slide 7: Global Business Strategy: Progress in Sales Currency Portfolio
Global Business Strategy: Progress in Sales Currency Portfolio Promoting diversification of sales currency portfolio to strengthen financial resilience against foreign exchange risks. Settlement in foreign currency exceeded the plan in the third quarter (more than 40%). ■ Sales Currency Portfolio Pe
Slide 8: Global Business Strategy: Progress in Applying New Unit Prices
Global Business Strategy: Progress in Applying New Unit Prices In anticipation of increasing global demand for IT personnel, especially advanced AI personnel, we have made steady progress in shifting to a high unit-price model from the current fiscal year. Enhancement of high-level human resources :
Slide 9: Global Business: Change and Outlook of Sales Composition by Strategic Field
Global Business: Change and Outlook of Sales Composition by Strategic Field We aim to expand the AI-related business by developing cutting-edge personnel. We will concentrate on the increase of orders received in the AI field toward FY2024. © Ubicom Holdings, Inc. 9
Slide 10: Global Business: Promote GO GLOBAL Strategy
Global Business: Promote “GO GLOBAL” Strategy To strengthen business strategies with an eye on the global market (1) Promote global M&A, investment and business alliances (2) Strengthen overseas marketing (U.S./Israel) (3) AI education through alliances with companies in digitally advanced countries
Slide 11: Global Business: Advancement of Business Model
Global Business: Advancement of Business Model Generate pillar clients and high profitability through flexible offshore/onsite development Definition of pillar clients: Constant clients that are market leaders in each field with sales scale of several 100 million yen Establishment of Offshore (our d
Slide 12: FY2022 3Q Segment Overview: Medical Business
FY2022 3Q Segment Overview: Medical Business Secured high profitability and a solid upward trend in profit FY2021 FY2022 Medical Business Year-on- Q3 Q3 Year (unit: million yen) Amount % to sales Amount % to sales Net Sales 1,115 100.0% 1,129 100.0% 101.2% Operating Income 627 56.2% 661 58.6% 105.5%
Slide 13: Medical Business: Advancement of Business Model
Medical Business: Advancement of Business Model Expansion of highly profitable foundation with the subscription model Trend of Medical Business Performance Sales Composition Trend of Medical Business (unit: million yen) *recurring ratio: continuous sales ratio 1,484 1,435 58.6% 1,282 1,301 57.0% 1,1
Slide 14: Medical Business: External Environment and Promotion of Business Strategy
Medical Business: External Environment and Promotion of Business Strategy Marketing of medical solution/platform concept in line with medical healthcare DX policy to began in this FY 2022 Q2. Started preparing for business qualification in 3Q with an eye on the medical platform business. ■External e
Slide 15: Medical Business: To Strengthen Sales Strategy
Medical Business: To Strengthen Sales Strategy Strengthening strategy to promote sales of the Mighty series Priority measures for the second half of FY 2022 and beyond ... direct sales/consulting Sales enhancements Feedback Customer Support ... building a user community ... strengthening cost-effect
Slide 16: Medical Business: Launch of Mighty QUBE Hybrid
Medical Business: Launch of the top-of-the-line product "Mighty QUBE Hybrid Official launch of the Mighty QUBE Hybrid (October 2022) Real-time checking system Mighty QUBE Hybrid Features Compatible with Medical Doctors’ Workstyle Reform 2024 Hybrid model compatible with cloud and on-premise syst
Slide 17: Medical Business: Effects of Mainstay Solutions
Medical Business: Effects of Mainstay Solutions ■Effects of Mighty Checker (MC) for Medical Affairs *1 (1) Reduction of operation time (2) Cost reduction and profit improvement Conventional medical claims inspection Inspection (Visual) of medical claims after introducing MC Inspection cost 100% Redu
Slide 18: Progress of Insurance Knowledge Platform
Progress of Insurance Knowledge Platform ■ Progress of projects under negotiation Currently in negotiation with 7 of the 50 companies in the life insurance market, including 3 companies with which PoC verification for installation in FY 2023 (next fiscal year) is underway. *At each insurance company
Slide 19: Medical Domain: Growth Potential of each Solution
Medical Domain: Growth Potential of each Solution To promote further improvement of average spending per customer and recurring revenue earning capability through up-selling, cross-selling, and direct sales Mighty QUBE + MQ Hybrid Identified nearly 1,000 new targets (mid-sized hospitals) towards Doc
Slide 20: Target Market Size for Medical Platforms
Target Market Size for Medical Platforms We aim to become the No. 1 platform in the niche medical field by leveraging our position as the market leader in DX solutions focused on medical institutions. New (domestic and overseas) Insurance Strategic Medical companies Markets institutions Insurance Kn
Slide 21: Medical Platform Utilization Strategy (Medium/Long-term Vision)
Medical Platform Utilization Strategy (Medium/Long-term Vision) To create more new markets through strategies to enclose the user community (potential market size: 300 billion yen*) *surveyed by our company ・Conversion of sales staff to consultants New market ・Medical engineer training Creation ・Str
Slide 22: Promotion of M&A strategy based on results of acquisition of subsidiaries
Promotion of M&A strategy based on the results of acquisition of subsidiaries We aim to actualize new M&A that would contribute to our platformer strategy, by utilizing the know-how of post-merger integration (PMI) for medical business. ■Successful cases of M&A: Variation in results of medical busin
Slide 23: FY2022 Q3 Major Releases and Topics
FY2022 Q3 Major Releases and Topics Decision to Relocate the Head Office (announced on October 20, 2022) The decision to relocate the head office was made to maximize the value of human capital for the realization of the second growth phase, to promote business innovation, and to improve the offic
Slide 24: FY2022 Priority measures
FY2022 Priority measures While paying attention to the profit balance, we will take measures for fortifying the base for the second growth phase. 1. To enrich expert resources that would contribute to “Go Global Strategy” 2. To enhance the recruitment and training of Filipino engineers 3. To beef up
Slide 25: ESG: Towards Sustainable Development of Business, Society & Customer
ESG: Towards Sustainable Development of Business, Society & Customer ■Global Business ・DX Support (Business process reforms for clients through advanced technology support such as AI/Analytics/Automation/Cloud) ・Improvement of Japan’s global competitiveness through globalization support for domestic
Slide 26: Promotion of the group business based on social meanings
Promotion of the group business based on social meanings Entire group Medical business Resilient management, Provision of solutions that are beneficial personnel development strategy, to all parties as they contribute to the business synergy, and pursuit of reform of doctors’ workstyles, the signifi
Slide 27: Promotion of the Leverage Strategy (the 2nd Growth Phase)
Promotion of the Leverage Strategy (the 2nd Growth Phase) To maximize the synergy between the existing business and M&A, and promote the development of new recurring-revenue/SaaS model ・Medical field Themes of the ・Pillar clients: + 20 companies ・Global market ×M&A second growth phase ・Sustainabilit
Slide 28: Company Overview
Company Overview ■Company name: Ubicom Holdings, Inc. (TSE Prime: 3937) ■Strategic industry: Medical, Financial/Public, Automotive, Manufacturing/Robotics, etc. ■Our Business: Global Business Dedicated in solving IT resource shortage in Japan and promoting DX (Digital Transformation), through provid
Slide 29: Cautionary Note on Forward Looking Statements
Cautionary Note on Forward Looking Statements This material may contain forward looking statements and forecasts regarding the future outlook at the time of publication. They are subject to risks and uncertainties including, but not limited to, domestic and international economic conditions such
Slide 30: © Ubicom Holdings, Inc.
© Ubicom Holdings, Inc.